MarketCap
Facebook
X
TelegramAnnual report 2025
added 11-19-2025
Enanta Pharmaceuticals Market Cap 2011-2026 | ENTA
As of January 13, 2026 Enanta Pharmaceuticals has a market cap of $ 277 K
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Enanta Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 259 K | 186 K | 190 K | 903 K | 1.42 M | 977 K | 1.2 B | 1.42 B | 945 M | 453 M | 525 M | 811 M | 195 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.42 B | 186 K | 427 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
87.8 M | $ 1.65 | 7.91 % | $ 92.9 M |  China |
 |
AstraZeneca PLC
AZN
|
81.2 B | $ 93.52 | -1.2 % | $ 96.9 B |  Britain |
 |
Autolus Therapeutics plc
AUTL
|
424 M | $ 1.52 | -16.3 % | $ 388 M | Britain |
 |
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.59 | 1.99 % | $ 8.64 B |  Australia |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B |  USA |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M |  France |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |
 |
Biogen
BIIB
|
19.3 B | $ 184.48 | -1.67 % | $ 26.9 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
BioNTech SE
BNTX
|
62.9 B | $ 102.17 | 2.32 % | $ 27.2 B | Germany |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.16 B | $ 4.25 | 1.67 % | $ 9.25 B |  Israel |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
7.37 B | $ 207.49 | 2.22 % | $ 5 B |  Danmark |
 |
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M |  Canada |
 |
Catalyst Biosciences
CBIO
|
33.6 M | $ 10.84 | 0.46 % | $ 714 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
2.05 B | - | -15.15 % | $ 60.3 M | Britain |
 |
Corcept Therapeutics Incorporated
CORT
|
6.55 B | $ 37.35 | -0.4 % | $ 3.86 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
2.44 B | $ 23.18 | 2.02 % | $ 2.75 B | USA |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | USA |
 |
Celldex Therapeutics
CLDX
|
1.31 M | $ 25.59 | -6.54 % | $ 1.65 M | USA |
 |
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
49 M | - | 4.14 % | $ 49.1 M | USA |
 |
Cellectis S.A.
CLLS
|
203 M | $ 4.22 | -4.2 % | $ 116 M | France |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | Israel |
 |
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.31 B | $ 29.43 | 6.09 % | $ 1.43 B | USA |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | USA |
 |
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
Brickell Biotech
BBI
|
11.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
2.09 B | $ 9.66 | 2.28 % | $ 1.53 B | Britain |
 |
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
5.65 B | - | -6.81 % | $ 3.04 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
6.25 B | $ 66.05 | 2.3 % | $ 8.83 B | USA |
 |
Athersys
ATHX
|
364 M | - | 3.77 % | $ 22.4 M | USA |
 |
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
2.7 B | $ 55.11 | 3.49 % | $ 4.45 B | USA |
 |
Abeona Therapeutics
ABEO
|
149 M | $ 5.14 | -1.06 % | $ 110 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
3.34 B | $ 55.17 | 2.47 % | $ 4.65 B |  Schweiz |
 |
AVROBIO
AVRO
|
56.3 M | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
39.8 B | $ 632.29 | 0.09 % | $ 47.9 B | USA |
 |
ADiTx Therapeutics
ADTX
|
59.2 K | $ 0.81 | 1.96 % | $ 10.7 K | USA |
 |
Aytu BioScience
AYTU
|
15.8 M | $ 2.7 | 2.27 % | $ 17 M | USA |